GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars
GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, setting up a potential FDA decision later this year and significantly boosting Spero’s stock. The companies ...
GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, setting up a potential FDA decision later this year and significantly boosting Spero’s stock.
The companies ...
